Feladilimab Uses, Dosage, Side Effects and more
Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma).
| Attribute | Details |
|---|---|
| Trade Name | Feladilimab |
| Generic | Feladilimab |
| Feladilimab Other Names | Feladilimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
